耐性ブドウ球菌トキソイドの治療効果判定に関する研究

概要

論文の詳細を見る
From 1936 onwards, Hosoya et al had prepared purified staphylococcal toxoid from cultures of sensitive staphylococcal strains and used it as a prophylactic and therapeutic agent against staphylococcal infections, with a striking beneficial effect on acute and chronic cases. Although this method threw much light upon the therapeutic aspects of such infections, the precise mechanism by which it can contribute much to inhibition of staphylococcal infections has been almost entirely unknown since that time. Difficulties in this elucidation of the mechanism arose from the fact that a parallel correlation between clinical improvement and elevation of antitoxin (anti-hemolysin) titers in human sera could not have been achieved in so many cases.<BR>Recently Soeda and Kitahara found a close relationship between inhibition of staphylococcal infections and the titers of specific precipitin in sera of both human and animal hosts. The patterns of variation in precipitin titers of host sera tend to well correlate with those of alteration in clinical response to toxoid therapy. It seems reasonable to consider that titration of antihemolysin induced by toxoid injection may contribute little, if any, to evaluation of therapeutic effect of toxoid and that titration of specific precipitin in host sera may be a more useful measure for the same purpose. Here I will report on the experimental results by which foregoing our views may be supported.
日本細菌学会の論文